Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Helicobacter Pylori | Research article

Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy

Authors: B. M. Donida, G. Tomasello, M. Ghidini, F. Buffoli, M. Grassi, W. Liguigli, G. Maglietta, L. Pergola, M. Ratti, G. Sabadini, L. Toppo, M. Ungari, R. Passalacqua

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The gastric cancer incidence rate differs widely across geographical areas. In Italy, in the province of Cremona the incidence is high, compared to the national situation. For this reason a specialized population-based registry was set up.

Methods

The collection encompasses all gastric cancers diagnosed in the three districts of the province since January 1, 2010. The main data sources were the pathological and Hospital Discharge Records and patient clinical charts. Only diagnoses of primary gastric cancer were considered. For each case the following variables were registered: personal data, medical history and symptoms at diagnosis; imaging assessments performed, details on surgery and other treatments received; genetic background and biomolecular characteristics; social and environmental factors.

Results

As of November 2017, 1087 cases were collected; of which 876, diagnosed up to December 2015, were analyzed. Male/female ratio was 1.4. The European Age-standardized Incidence Rate was 41.4 for males and 28.3 for females as compared to a national average of 33.3 and 17.0 respectively. Median age at diagnosis was 73 for male and 78 for female. Helicobacter Pylori infection was present in fewer than 20% of cases. HER-2 gene was amplified in about 25% of cases. Primary tumour location was the gastro-esophageal junction or cardia in 17.5% in males and 8.3% in females. The majority of cases (58.3%) were diagnosed at an advanced stage and overall only 41.2% underwent surgery. Median overall survival was 14.8 months for men and 18.5 for women. Age standardized 5-year relative survival was 31.4% for men and 40.5% for females. Neoadjuvant treatment was performed in fewer than 10% of patients who underwent surgery, and the rate of postoperative therapy adherence was low.

Discussion

This study shows a high gastric cancer incidence in the province of Cremona, with a geographical spread across different districts. Moreover, a high percentage of gastric cancers were detected at an advanced stage of disease and a low rate of 5-year relative survival was registered. Based on these findings, effective preventive interventional health strategies and screening procedures need to be implemented to reduce the impact of this pathology in this geographical area.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr; accessed on 26th Nov 2017.
2.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74e108.CrossRef
3.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999e2007 by country and age: results of UROCAREe5-a population-based study. Lancet Oncol. 2014;15:23e34.CrossRef
4.
Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992e2009 SEER data. Dig Dis Sci. 2014;59(12):3027–34.CrossRef
5.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.CrossRef
6.
Tahara T, Shibata T, Nakamura M, Yoshioka D, Okubo M, Arisawa T, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc. 2009;70(2):246–53.CrossRef
7.
I numeri del cancro in Italia 2017, Aiom-AIRTum, Intermedia Ed, 2017.
8.
Cislaghi C, Dal Cason M, Tasco C, Braga M. Geographic distribution of digestive system tumour mortality in Italy, 1970-87. Ann Ist Super Sanità. 1996;32(4):453–69.PubMed
9.
Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156–69.CrossRef
10.
Ferretti S et AIRTum working group, Manuale di Tecniche di Registrazione dei Tumori, Inferenze Scarl, ed. 2007.
11.
Cancer Registration: Principles and Methods, World Health Organization International Agency for Research on Cancer and International Association of Cancer Registries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. IARC Scientific Publication No. 95, 1991. ISBN 92 832 1195 2.
12.
International Agency for Research on Cancer IARC. Cancer in 5 continents. In: Waterhouse JAH, Muir CS, Shanmugaratnam K, Powell J, editors. IARC Scientific Publication no. 42., 1982. ISBN 978–92–832-1142-6.
13.
TNM Classification of Malignant Tumours, 7th edition. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. Oxford: Wiley-Blackwell 2011. ISBN 978–1–444-35896-4.
14.
Cancer Staging Manual AJCC. 7th edition. In: Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A, editors. New York. NY: Springer; 2010.
15.
Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13:2–9.CrossRef
16.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRef
17.
Corso G, Seruca R, Roviello F. Gastric cancer carcinogenesis and tumour progression. Ann Ital Chir. 2012;83(3):172–6 PMID: 22595727.PubMed
18.
19.
Van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74.CrossRef
20.
Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–44.CrossRef
21.
Kluijt I, Sijmons RH, Hoogerbrugge N, Plukker JT, de Jong D, van Krieken JH, et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer. 2012;11(3):363–9. 50.CrossRef
22.
23.
Cancer incidence in five continents. In: Waterhouse JAH, Muir CS, Correa P, Powell J, editors. Lyon: IARC, 1976; Vol. 3: 456.
24.
Eurostat European Commission. Revision of the Standard Population. Ed. European Union, 2013, ISSN 1977–0375, available at http://​europa.​eu (last accessed on May 25 2018).
25.
Cancer Mortality for Selected Sites in 24 Countries (1950–57). In: Segi M editor. Department of Public Health, Tohoku University of Medicine, Sendai, Japan, 1960.
26.
Cancer Incidence in Five Continents. In: Doll, R, Payne, P, Waterhouse, JAH, editors Vol. I, 1966. Union Internationale Contre le Cancer, Geneva.
27.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
28.
29.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for join point regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRef
30.
Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977;30:431–43.CrossRef
31.
Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer. 2004;40:2494–501.CrossRef
32.
Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78:2004–10.CrossRef
33.
Ederer F, Heise H. 1959. Instructions to IBM 650 programmers in processing survival computations. Methodological note 10. End results evaluation section, National Cancer Institute, Bethesda, MD; 1959.
34.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
35.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer. 1977;35:1–39.CrossRef
36.
37.
Fitzgerald RC, Caldas C. Familial gastric cancer-clinical management. Best Pract Res Gastroenterol. 2006;20:735–43.CrossRef
38.
Kim S, Chung JW, Jeong TD, Park YS, Lee JH, Ahn JY, et al. Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Familial Cancer. 2013;12:503–7.52.CrossRef
39.
Choi HJ, Ki CS, Suh SP, Kim JW. Presymptomatic identification of CDH1 germline mutation in a healthy korean individual with family history of gastric cancer. Ann Lab Med. 2014;34:386–9.CrossRef
40.
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-5.
41.
Yamada M, Fukagawa T, Nakajima T, Asada K, Sekine S, Yamashita S, et al. Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. Gastric Cancer. 2014;17:750–6.CrossRef
42.
Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18(9):1545–55.CrossRef
43.
Yamada H, Shinmura K, Ito H, Kasami M, Sasaki N, Shima H, et al. Germline alterations in the CDH1 gene in familial gastric cancer in the Japanese population. Cancer Sci. 2011;102(10):1782.CrossRef
44.
Helicobacter and Cancer Collaborative Group. Gastric cancer and helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347–53.CrossRef
45.
46.
47.
48.
49.
50.
51.
52.
Van Leeuwen JA, Waltner-Toews D, Abernathy T, Smit B, Shoukri M. Associations between stomach cancer incidence and drinking water contamination with atrazine and nitrate in Ontario (Canada) agroecosystems, 1987-1991. Int J Epidemiol. 1999;28(5):836–40.CrossRef
53.
Cremona in one day. In: Enrico Massetti E, editor. 2015 pp. 35–38. ISBN 978–1–312-89500-3.
Metadata
Title
Epidemiological, clinical and pathological characteristics of gastric neoplasms in the province of Cremona: the experience of the first population-based specialized gastric cancer registry in Italy
Authors
B. M. Donida
G. Tomasello
M. Ghidini
F. Buffoli
M. Grassi
W. Liguigli
G. Maglietta
L. Pergola
M. Ratti
G. Sabadini
L. Toppo
M. Ungari
R. Passalacqua
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5366-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Study protocol

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

Research article

The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

Case report

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report

Research article

Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis

Research article

Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review

Research article

Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits